Laboratory for Pain Research, University of Split School of Medicine, Šoltanska 2, 21000, Split, Croatia.
Department of Anesthesiology, Reanimatology and Intensive Care, University Hospital Split, Spinčićeva 1, 21000, Split, Croatia.
BMC Anesthesiol. 2020 May 4;20(1):105. doi: 10.1186/s12871-020-01023-9.
We systematically reviewed the evidence on the efficacy and safety of dorsal root ganglion (DRG) targeted pulsed radiofrequency (PRF) versus any comparator for treatment of non-neuropathic pain.
We searched MEDLINE, CINAHL, Embase, PsycINFO, clinicaltrials.gov and WHO clinical trial register until January 8, 2019. All study designs were eligible. Two authors independently conducted literature screening. Primary outcomes were pain intensity and serious adverse events (SAEs). Secondary outcomes were any other pain-related outcome and any other safety outcome that was reported. We assessed the risk of bias using the Cochrane tool and Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I). We conducted narrative evidence synthesis and assessed the conclusiveness of included studies regarding efficacy and safety.
We included 17 studies with 599 participants, which analyzed various pain syndromes. Two studies were randomized controlled trials; both included participants with low back pain (LBP). Non-randomized studies included patients with the following indications: LBP, postsurgical pain, pain associated with herpes zoster, cervicogenic headache, complex regional pain syndrome type 1, intractable vertebral metastatic pain, chronic scrotal and inguinal pain, occipital radiating pain in rheumatoid arthritis and chronic migraine. In these studies, the PRF was usually initiated after other treatments have failed. Eleven studies had positive conclusive statements (11/17) about efficacy; the remaining had positive inconclusive statements. Only three studies provided conclusiveness of evidence statements regarding safety - two indicated that the evidence was positive conclusive, and one positive inconclusive. The risk of bias was predominantly unclear in randomized and serious in non-randomized studies.
Poor quality and few participants characterize evidence about benefits and harms of DRG PRF in patients with non-neuropathic pain. Results from available studies should only be considered preliminary. Not all studies have reported data regarding the safety of the intervention, but those that did, indicate that the intervention is relatively safe. As the procedure is non-destructive and early results are promising, further comparative studies about PRF in non-neuropathic pain syndromes would be welcomed.
我们系统地回顾了背根神经节(DRG)靶向脉冲射频(PRF)治疗非神经性疼痛的疗效和安全性证据,与任何对照相比。
我们检索了 MEDLINE、CINAHL、Embase、PsycINFO、clinicaltrials.gov 和世卫组织临床试验注册中心,截至 2019 年 1 月 8 日。所有研究设计均符合条件。两名作者独立进行文献筛选。主要结局指标是疼痛强度和严重不良事件(SAEs)。次要结局指标是报告的任何其他与疼痛相关的结局和任何其他安全性结局。我们使用 Cochrane 工具和干预措施非随机研究的偏倚风险(ROBINS-I)评估偏倚风险。我们进行了叙述性证据综合,并评估了纳入研究在疗效和安全性方面的结论性。
我们纳入了 17 项研究,共 599 名参与者,分析了各种疼痛综合征。两项研究为随机对照试验;均纳入了腰痛(LBP)患者。非随机研究包括以下适应证的患者:LBP、手术后疼痛、带状疱疹相关疼痛、颈源性头痛、复杂性区域疼痛综合征 1 型、难治性椎体转移性疼痛、慢性阴囊和腹股沟疼痛、类风湿关节炎和慢性偏头痛的枕部放射痛。在这些研究中,PRF 通常在其他治疗失败后开始。11 项研究对疗效有明确的阳性结论(11/17);其余的有阳性不确定的结论。只有 3 项研究提供了安全性证据结论的结论性——2 项表明证据是阳性的,1 项是阳性不确定的。随机研究的偏倚风险主要不明确,非随机研究的偏倚风险严重。
在非神经性疼痛患者中,DRG PRF 益处和危害的证据质量差且参与者少。现有研究的结果只能被认为是初步的。并非所有研究都报告了干预安全性的数据,但那些报告了数据的研究表明,该干预相对安全。由于该程序是非破坏性的,早期结果很有希望,因此欢迎对非神经性疼痛综合征中的 PRF 进行进一步的比较研究。